Research - Page 50 of 720 Posts on Medivizor
Navigation Menu

Research Posts on Medivizor

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Posted by on Sep 12, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at whether radiotherapy had an impact on the recurrence rate in patients with early-stage Hodgkin lymphoma (HL). It found that in patients with early-stage HL who responded fully to chemotherapy, the addition of radiotherapy reduced the risk of localized recurrence.  Some background Early-stage...

Read More

What are the most common skin-related side effects of immune therapy for patients with melanoma?

What are the most common skin-related side effects of immune therapy for patients with melanoma?

Posted by on Sep 12, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the skin-related side effects of immune checkpoint inhibitors in the treatment of melanoma. It found that the most common side effects were mild-to-moderate itching, rash, and vitiligo (loss of skin pigment).   Some background Immune checkpoint inhibitors (ICIs) are a type of immune therapy used to...

Read More

Have COVID-19 restrictions negatively affected people with Parkinson’s disease?

Have COVID-19 restrictions negatively affected people with Parkinson’s disease?

Posted by on Sep 12, 2021 in Parkinson's Disease | 0 comments

In a nutshell This study looked at how motor symptoms progressed in patients with Parkinson's disease (PD), before and during the COVID-19 pandemic. It found that motor symptoms progressed more quickly during the first 15 months of the pandemic than during the 15 months before it. Some background PD symptoms involving muscles and...

Read More

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use and response of the Pfizer BioNTech COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma (NHL). It found that patients with NHL undergoing treatment with rituximab (Rituxan)/obinutuzumab (Gazyva) had a poorer immune response to this vaccine, compared to patients without...

Read More

Long term outcomes and risk factors for patients with advanced chronic myeloid leukemia who have undergone allogeneic stem cell transplantation

Long term outcomes and risk factors for patients with advanced chronic myeloid leukemia who have undergone allogeneic stem cell transplantation

Posted by on Sep 5, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to determine the long-term outcomes and risk factors after allogeneic stem cell transplantation (allo-SCT) for patients with advanced phase chronic myeloid leukemia (CML).  This study concluded that allo-SCT improved the outcomes of these patients, particularly in those with donors younger than 36...

Read More

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Sep 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients. Some background mCRPC is an...

Read More

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Posted by on Sep 5, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of preventative antibiotic treatment with clarithromycin (Biaxin) to prevent skin-related side effects associated with panitumumab (Vectibix) treatment for patients with metastatic colorectal cancer (mCRC). The data showed that clarithromycin administered daily along with a simple...

Read More

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Posted by on Sep 5, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) on health-related quality of life (HR-QoL) in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC). The data showed that this combination preserved HR-QoL in these patients. Some...

Read More

Do blood pressure medications help to improve signs of brain small vessel disease?

Do blood pressure medications help to improve signs of brain small vessel disease?

Posted by on Sep 5, 2021 in Hypertension | 0 comments

In a nutshell This study looked at the effect of blood pressure (BP)-lowering medications on cerebral small vessel disease (CVSD). It found that maintaining systolic blood pressure (SBP; BP when the heart beats) between 110-129 mmHg reduced the progression of white matter hyperdensities, one of the signs of CVSD on brain scans. Some background...

Read More

Does canagliflozin reduce the risk of hospitalization in patients with type 2 diabetes?

Does canagliflozin reduce the risk of hospitalization in patients with type 2 diabetes?

Posted by on Sep 5, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the effect of canagliflozin (Invokana) on hospitalization occurrence in patients with type 2 diabetes (T2D). It found that patients treated with canagliflozin were less likely to be admitted to the hospital than patients treated with placebo.  Some background Canagliflozin is a medication...

Read More